Clinicians treating patients with COVID-19  who are at risk for progression to acute disease should be aware of potential drug–drug interactions when the oral antiviral treatment nirmatrelvir/ritonavir (Paxlovid—Pfizer) is administered to people taking common cardiovascular drugs, experts warn in a new Journal of the American College of Cardiology article.

Cheering and laughter overpowered the room as we all joined together for the APhA–ASP Opening General Session (OGS) at the APhA Annual Meeting & Exposition in March. The crowd filled with excitement as the APhA–ASP National Executive Committee stood together on stage. The journey to this moment has helped build strong relationships and longtime friendships, creating a magical experience that will not be forgotten.